文献速递脊柱关节炎

Filgotinib对活动性银屑病关节炎健康相关生活质量的影响:EQUATOR随机2期试验

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

结果显示,filgotinib组PsAID9总分及所有领域较基线改善均显著优于安慰剂,达到MCII和PASS的患者比例也显著更高,且与SF-36改善呈中至强负相关。

要点

  • Filgotinib 200 mg每日一次治疗16周可显著改善活动性PsA患者的HRQoL(PsAID9)。
  • 第16周PsAID9总分组间差异为-1.48(95%CI -2.12, -0.84),P<0.0001。
  • Filgotinib组达到MCII和PASS的比例显著高于安慰剂组。

核心结论

  • Filgotinib 200 mg每日一次治疗16周可显著改善活动性银屑病关节炎患者的健康相关生活质量,且所有PsAID9领域均优于安慰剂。

主要发现

  • 第16周PsAID9较基线平均(标准差)变化:filgotinib组为-2.3(1.8),安慰剂组为-0.8(2.2),组间最小二乘均值差异为-1.48(95%CI -2.12, -0.84),P<0.0001。
  • 第16周filgotinib组达到MCII的患者比例显著高于安慰剂组,组间差异为25.4%(95%CI 8.92, 39.99),P=0.0022。
  • 第16周filgotinib组达到PASS的患者比例显著高于安慰剂组,组间差异为29.6%(95%CI 10.65, 45.60),P=0.0018。
  • SF-36观察到类似改善,PsAID9与SF-36之间呈中至强负相关。

关键数值与推荐

  • MCII定义为PsAID9评分改善≥3分。
  • PASS定义为PsAID9评分<4。

临床怎么用

  • 对于活动性银屑病关节炎患者,filgotinib 200 mg每日一次治疗至第4周即可观察到PsAID9改善,至第16周在总体及所有领域均显著优于安慰剂。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effects of filgotinib, an oral, selective Janus kinase 1 inhibitor, on health-related quality of life (HRQoL) using the Psoriatic Arthritis Impact of Disease (PsAID)9 questionnaire in active PsA. METHODS: Patients were randomized 1 : 1 to filgotinib 200 mg or placebo once daily for 16 weeks in EQUATOR, a multicentre, double-blind, phase 2 randomized controlled trial. HRQoL was assessed with PsAID9 at Weeks 4 and 16. Change from baseline in total and individual domain scores, plus the proportions of patients achieving minimal clinically important improvement (MCII; ⩾3 points) and patient-accepted symptom status (PASS; score <4), were evaluated. Correlation with the 36-item short-form health survey (SF-36) was investigated. RESULTS: One hundred and thirty-one patients were randomized to filgotinib or placebo. Filgotinib effects on PsAID9 were observed from Week 4. At Week 16, mean (s.d.) change from baseline in PsAID9 was -2.3 (1.8) and -0.8 (2.2) for filgotinib and placebo, respectively (least-squares mean of group difference -1.48 [95% CI -2.12, -0.84], P < 0.0001), with significant improvements in all domains vs placebo. Significantly more patients on filgotinib achieved MCII (group difference 25.4% [95% CI 8.92, 39.99], P = 0.0022) and PASS (group difference 29.6% [95% CI 10.65, 45.60], P = 0.0018) at Week 16 vs placebo. Similar improvements in SF-36 were observed, with moderate to strong negative correlation between PsAID9 and SF-36. CONCLUSION: Filgotinib significantly improved HRQoL vs placebo in patients with active PsA, as measured by PsAID9. To our knowledge, EQUATOR is the first randomized controlled trial to evaluate PsAID9. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show, NCT03101670.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Orbai AM, Ogdie A, Gossec L, et al. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology (Oxford). 2020. PMID: 31624837. doi:10.1093/rheumatology/kez408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。